Ixico Regulatory News (IXI)

5 Sep 2006 07:01

Phytopharm PLC05 September 2006 Board Changes GODMANCHESTER, Cambridgeshire, U.K. (5th September 2006) - Phytopharm plc (LSE:PYM; NASDAQBB: PHYOF; PHYOY) ("Phytopharm") announces that Gordon Stevens(non-executive Chairman) and Trevor Flanagan (non-executive Director) have todayretired from the Board and that Paul Whitney (currently Deputy Chairman) hastoday stepped up to the role of non-executive Chairman. This reorganisation follows the recent appointments of two non-executiveDirectors - Dr Peter Blower, former Director of New Neuroscience products atSmithKline Beecham, and Sandy Morrison, former CEO of Lipton Ltd, a Unileversubsidiary. Gordon Stevens said; "I am pleased to be handing over the Chairman's role toPaul Whitney. Phytopharm has an excellent team, and with the recent strongadditions to the Board I believe the Company is well placed for much-deservedsuccess." Paul Whitney said; "On behalf of the Board of Phytopharm and myself personally,I would like to thank Gordon and Trevor for their enthusiasm and energy over thelast 10 years. We wish them well in their future activities." NOTES TO EDITORS Phytopharm plc Phytopharm is a pharmaceutical company with a plant extract division. Thepharmaceutical division is dedicated to the discovery and development of singlechemicals as prescription medicines and the plant extract division is focussedon the development of plant extracts as functional foods and veterinaryproducts. More information concerning Phytopharm's activities can be found on its websiteat http://www.phytopharm.com Company Contact: U.K. Investor Relations Contact:Phytopharm plc Financial DynamicsDr Richard Dixey David Yates / Ben Atwell+44 7867 782000 +44 207 831 3113Dr Daryl Rees+44 1480 437 697www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange